Citadel Advisors’s Benitec Biopharma BNTC Stock Holding History

Citadel Advisors’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.83M	Buy	171,722 +154,142	+877%	+$1.78M	﹤0.01%	6263
2025 Q4	$237K	Buy	+17,580	New	+$243K	﹤0.01%	10678
2024 Q4	–	Sell	-14,244	Closed	-$131K	–	14530
2024 Q3	$131K	Buy	+14,244	New	+$127K	﹤0.01%	10743
2023 Q4	–	Sell	-69,515	Closed	-$210K	–	14296
2023 Q3	$210K	Buy	+69,515	New	+$216K	﹤0.01%	9808
2022 Q3	–	Sell	-2,939	Closed	-$58K	–	12636
2022 Q2	$58K	Buy	+2,939	New	+$68.3K	﹤0.01%	11839
2021 Q3	–	Sell	-1,201	Closed	-$87K	–	13815
2021 Q2	$87K	Sell	1,201 -167	-12%	-$13.1K	﹤0.01%	13025
2021 Q1	$120K	Buy	+1,368	New	+$93K	﹤0.01%	12293
2019 Q3	–	Sell	-128	Closed	-$24K	–	9164
2019 Q2	$24K	Buy	+128	New	+$51.9K	﹤0.01%	8913
2018 Q4	–	Sell	-47	Closed	-$30K	–	9112
2018 Q3	$30K	Buy	+47	New	+$32.1K	﹤0.01%	8930
2017 Q1	–	Sell	-63	Closed	-$25K	–	7441
2016 Q4	$25K	Buy	+63	New	+$24K	﹤0.01%	7032

Other funds holding BNTC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Citadel Advisors's BNTC Position: Q1 2026 in Review

Citadel Advisors increased its Benitec Biopharma (BNTC) stake by 877% in Q1 2026, buying an estimated $1.78M and bringing the position to 171,722 shares worth $1.83M. The position accounts for ﹤0.01% of the portfolio, ranked #6263.

Citadel Advisors first reported a position in BNTC in Q4 2016 and has held it in 10 quarters since. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

Citadel Advisors held 171,722 shares of Benitec Biopharma worth $1.83M as of Q1 2026.
Citadel Advisors bought 154,142 Benitec Biopharma shares in Q1 2026, an estimated $1.78M.
Benitec Biopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6263 holding.
Citadel Advisors first reported a position in Benitec Biopharma in Q4 2016 and has held it in 10 quarters since.
88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.